CV at a glance
CapsoVision, Inc (CV, SEC CIK 1378325) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as September 23, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CapsoVision, Inc (CV) reported revenue of $13.6 million (up 15.3% from FY2024) and a net loss of $25.3 million. Diluted EPS was -$1.03.
- As of June 30, 2026, 15 institutional investment managers tracked by SignalX reported holding CapsoVision, Inc (CV) shares worth $30.9 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by HARARI ELIYAHOU ET AL on September 18, 2026 of 878,735 shares at $5.69 per share.
- In the last 90 days, CV insiders reported 5 open-market purchases ($20.4M) and 0 open-market sales ($0) on Form 4, a net purchase of $20.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $13.6M
- +15.3% vs prior year
- Insiders · 90 days
- 5 buys · 0 sells
- Net +$20.4M
- 13F holders
- 15 funds
- $30.9M · +1 vs prior quarter
- Latest 8-K
- Sep 28, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $3.643M, up 10% YoY from $3.315M, driven by 13% higher CapsoCam Plus unit sales
- Gross margin 51% vs 55% YoY; operating loss $7.580M vs $4.651M
- R&D expenses $5.309M, up 57% YoY, primarily clinical trials and Canon CMOS sensor development
- Six-month customs and tariffs added $0.1M; management cited competitive pricing pressure and tariff headwinds
- CapsoCam Colon pivotal study enrollment completed with 801 patients; 510(k) submission expected Q4 2026
Risk Factors
- New pancreatic-cancer study triggered by January 2026 FDA rejection of Breakthrough Device Designation application
- Going-concern risk intensified with $9.1 million cash and additional financing likely before year-end 2026
- FDA clearance risk for second-generation CapsoCam Colon tied to planned fourth-quarter 2026 510(k) submission
- Market concentration in CapsoCam Plus small-bowel sales, with CapsoCam Colon revenue not expected until FDA clearance
- Taiwan and Japan supply exposure, including single-source suppliers and heightened Taiwan Strait tensions
AI summary of the CV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- FDA clearance received September 25, 2026 for AI Highlights, expanding CapsoVision’s U.S. commercial product offering
- Tool targets suspected small bowel bleeding studies in adults and children over age 2
Item 8.01: Other Events
- FDA clearance received September 25, 2026 for AI Highlights™, an AI-assisted reading feature
- Feature integrates with CapsoCam Plus®, potentially strengthening product differentiation
Item 1.01: Entry into a Material Definitive Agreement
- Registered direct offering of 3,163,444 shares at $5.69, approximately 5% below September 16 market price
- Approximately $18 million gross proceeds, with closing expected September 18, 2026
Item 8.01: Other Events
- $100 million at-the-market equity program with Cantor Fitzgerald as sales agent
- Flexible capital access, allowing share issuance at management’s discretion
AI summaries of CV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CV
Don't miss the next CV filing
- Alerts as it files. A push when CV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CV, by share count.
- Ask anything. An AI agent that reads every CV filing and answers with sources.
CV alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| HARARI ELIYAHOU ET AL | Buy | Sep 18, 2026 | 878,735 | $5.69 |
| HARARI ELIYAHOU ET AL | Buy | Sep 18, 2026 | 878,734 | $5.69 |
| Shen Ching Hang | Buy | Sep 15, 2026 | 878,734 | $5.69 |
| Shen Ching Hang | Buy | Sep 15, 2026 | 878,734 | $5.69 |
| HARARI ELIYAHOU ET AL | Buy | Jul 17, 2026 | 61,068 | $6.73 |
| HARARI ELIYAHOU ET AL | Buy | Jul 8, 2026 | 81,300 | $6.09 |
| Shields David Stanley | A | Jul 1, 2026 | 1,710 | - |
| Kuo Hui Ying | M | Jun 30, 2026 | 2,022 | $7.58 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $11.8M | $13.6M |
| Gross Profit | - | $6.4M | $7.2M |
| Operating Income | - | -$19.9M | -$25.5M |
| Net Income | - | -$19.9M | -$25.3M |
| Gross Margin | - | 54.2% | 52.9% |
| Op. Margin | - | -169.4% | -188.3% |
| Net Margin | - | -169.3% | -186.8% |
| Balance Sheet | |||
| Total Assets | - | $16.8M | $18.2M |
| Equity | -$109.8M | -$129.5M | $13.3M |
| ROE | - | 15.4% | -190.9% |
| Per Share | |||
| EPS | - | $-9.85 | $-1.03 |
| Cash Flow | |||
| Operating CF | - | -$20.1M | -$22.9M |
| CapEx | - | $153K | $90K |
Source: XBRL data in CapsoVision, Inc (CV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 15 | $30.9M |
| Q1 2026 | 14 | $22.4M |
| Q4 2025 | 11 | $5.7M |
| Q3 2025 | 10 | $1.1M |
- BlackRock+591.7K (+45%)
- State Street Corp+154.2K (+60%)
- Vanguard Portfolio Management LLC+76.0K (+46%)
- Northern Trust+67.8K (+44%)
- Vanguard Capital Management LLC+32.2K (+3%)
- Goldman Sachs Group−17.5K (-48%)
- Invesco Ltd+18.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 50 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 8-K | Sep 18, 2026 | - | Analysis | - |
| 8-K | Aug 18, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
- LIVN · LivaNova PLCElectromedical & Electrotherapeutic Apparatus
CV SEC filings: frequently asked questions
Are CV insiders buying or selling?
In the last 90 days, CapsoVision, Inc (CV) officers, directors and 10% owners reported 5 open-market purchases worth $20.4 million by 2 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CV stock?
As of June 30, 2026, the largest CapsoVision, Inc (CV) holders among the 13F filers tracked by SignalX were BlackRock ($14.4 million), Vanguard Capital Management LLC ($8.0 million), State Street Corp ($3.1 million), Vanguard Portfolio Management LLC ($1.8 million), Northern Trust ($1.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CapsoVision, Inc (CV) reported revenue of $13.6 million (up 15.3% from FY2024) and a net loss of $25.3 million. Diluted EPS was -$1.03. The figures come from the XBRL data in the 10-K.
What did CV report in its latest 8-K?
CapsoVision, Inc (CV) filed an 8-K on September 28, 2026 reporting Item 8.01 (Other Events). FDA clearance received September 25, 2026 for AI Highlights, expanding CapsoVision’s U.S. commercial product offering.
What are the latest CV SEC filings?
CapsoVision, Inc (CV) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on September 23, 2026.
What is CV's SEC CIK number?
CapsoVision, Inc (CV)'s SEC Central Index Key (CIK) is 1378325. EDGAR lists every CV filing under that number.
Ask anything about CV
The research agent reads CV's filings, financials, insider trades and 13F holders, then answers with sources.